bit.bio appoints Przemek Obloj as new interim CEO following conclusion of Jonathan Milner’s tenure

bit.bio’s interim CEO is Przemek Obloj, who steps up from his role as chief finance officer to become the third leader at the synthetic biology company in as many months.

The appointment follows a busy December which saw a $30m finance round and co-founder Mark Kotter relinquishing the CEO reins to assume the role of vice-chairman of the board of directors. Jonathan Milner took on the role of interim CEO of bit.bio at the start of the year.

Dr Kotter said at the time he would “work closely with Jonathan and the team to help shape bit.bio’s future and establish bit.bio as the leading provider of human cells for research, drug discovery and the preferred partner for iPSC-derived cell therapies”.

Dr Milner, a long-term Cambridge company builder, investor, board member and mentor since co-founding Abcam in 1998, was also a long-term investor in bit.bio and a business mentor to Dr Kotter, who is a neurosurgeon and stem cell biologist as well as an investor (clock.bio, Meatable) and entrepreneur.

A spokesperson for bit.bio said that this reshaping process has meant that “we’re undergoing strategic realignments to position the company for long-term success”.

The spokesperson added: “This follows our December financing round, which strengthened our foundation.

“Jonathan, as an early investor, has been instrumental in this effort. Over the past several weeks, he’s invested considerable time and energy working closely with the executive team and board to help guide our future strategy, and we’re incredibly grateful for his business insights and collaborative leadership during this period.

“Following this strategy evaluation, Przemek Obloj will step in as interim CEO. The board and investors have full confidence in him to move the company forward.”